196 related articles for article (PubMed ID: 23445611)
1. Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer.
Yin S; Xu L; Bonfil RD; Banerjee S; Sarkar FH; Sethi S; Reddy KB
Mol Cancer Ther; 2013 Apr; 12(4):491-8. PubMed ID: 23445611
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells.
Xu L; Yin S; Banerjee S; Sarkar F; Reddy KB
Mol Cancer Ther; 2011 Mar; 10(3):550-7. PubMed ID: 21252285
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and TRAIL enhance breast cancer stem cell death.
Yin S; Xu L; Bandyopadhyay S; Sethi S; Reddy KB
Int J Oncol; 2011 Oct; 39(4):891-8. PubMed ID: 21687939
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
[TBL] [Abstract][Full Text] [Related]
5. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
[No Abstract] [Full Text] [Related]
6. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
9. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
[TBL] [Abstract][Full Text] [Related]
10. Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment.
Yin S; Rishi AK; Reddy KB
Oncol Rep; 2015 Mar; 33(3):1475-80. PubMed ID: 25592673
[TBL] [Abstract][Full Text] [Related]
11. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.
Garimella SV; Rocca A; Lipkowitz S
Mol Cancer Res; 2012 Jan; 10(1):75-85. PubMed ID: 22112940
[TBL] [Abstract][Full Text] [Related]
12. Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation.
Al-Sharif I; Remmal A; Aboussekhra A
BMC Cancer; 2013 Dec; 13():600. PubMed ID: 24330704
[TBL] [Abstract][Full Text] [Related]
13. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73.
Tiwary R; Yu W; Sanders BG; Kline K
Breast Cancer Res; 2011 Jan; 13(1):R1. PubMed ID: 21214929
[TBL] [Abstract][Full Text] [Related]
14. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
Tsai HC; Huang CY; Su HL; Tang CH
PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
[TBL] [Abstract][Full Text] [Related]
15. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
Harashima N; Takenaga K; Akimoto M; Harada M
Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
[TBL] [Abstract][Full Text] [Related]
17. β-catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer.
Ouyang W; Zhang S; Yang B; Yang C; Zhang J; Zhou F; Xie C
Oncol Rep; 2016 Feb; 35(2):717-24. PubMed ID: 26717875
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model.
Rossini A; Giussani M; Giacomini A; Guarnotta C; Tagliabue E; Balsari A
Breast Cancer Res Treat; 2012 Nov; 136(2):457-67. PubMed ID: 23053664
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
20. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
